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A B S T R A C T
Background: Antibody mediated anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a recently
reported diagnosis of clinical importance. Recognition of the syndrome, especially in pediatric
populations, is difﬁcult and often undiagnosed and/or confused with neurological disorders with similar
clinical features.
Results: We report a case of an 11 year old female with explosive-onset epilepsy and predominantly
unilateral frontal lobe abnormalities on magnetic resonance imaging (MRI) and ﬂuorodeoxyglucose
positron emission tomography (FDG-PET) neuroimaging. A diagnosis of Rasmussen syndrome (RS) was
considered. Cerebrospinal ﬂuid analysis revealed strong positivity for NMDA receptor antibodies.
Screening for occult ovarian teratoma with computed tomography (CT) and MRI initially did not
demonstrate associated tumor. Treatment with steroids and plasma exchange improved her clinical
course and subsequent MRI showed resolution.
Conclusion: NMDA receptor encephalitis has variable neuroimaging manifestations, and can mimic
other entities. We emphasize the clinical syndrome of NMDA receptor encephalitis and consideration of
the diagnosis in evaluating a child with explosive-onset epilepsy, unilateral imaging abnormalities, and
neurocognitive decline.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Anti-NMDA-receptor (NMDAR) encephalitis is an acute auto-
immune paraneoplastic syndrome that can occur with or without
identiﬁable associated tumors, commonly presenting in young
women with occult ovarian teratoma. The clinical features were
initially described in 1997 in a 19 year old woman with limbic
encephalitis which improved after removal of an ovarian terato-
ma.1 The identiﬁcation of disease-causing antibodies was not
made until 2007.2 NMDAR encephalitis is characterized by
prominent subacute, progressive neuropsychiatric signs and
symptoms, including depression and catatonia, and can progress
to death or disability in many cases.3 Seizures, headaches,
disordered sleep and movement disorders, including orofacial
dyskinesias, also occur in a majority of patients. In addition,
patients may develop hypoventilation, dysautonomia, and coma.2
The overall clinical course is variable, ranging from full recovery to* Corresponding author at: Cincinnati Children’s Hospital Medical Center, 3333
Burnet Avenue, MLC 2015, Cincinnati, OH 45229, USA. Tel.: +1 513 636 9214;
fax: +1 513 636 1888.
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doi:10.1016/j.seizure.2010.11.013death. Relapses may occur. The syndrome has been most
frequently reported in young women, but identiﬁcation of NMDAR
encephalitis occurring in children as young as 2 and 3 years of age
is increasing.4,5 However, in males and prepubertal girls, the
association with tumor is more rare than that reported in adults.4
The differential diagnosis in presenting cases leads clinicians to
a broad and extensive evaluation. NMDAR encephalitis has no
speciﬁc ﬁndings on standard brain magnetic resonance imaging
(MRI), cerebrospinal ﬂuid analysis (CSF), or electroencephalogram
(EEG) evaluation. Nonspeciﬁc abnormalities on ﬂuid attenuated
inversion recovery (FLAIR) sequences of MRI are common, not only
in the medial temporal lobes but also in the basal ganglia,
cerebellum, and cerebral cortex.3 CSF pleocytosis is seen in 89–95%
of reported cases. CSF oligoclonal bands are less frequently seen
but have been consistently reported.3,4,6 EEG typically shows focal
delta or theta waves, and subclinical seizures are frequently
reported. Due to these nonspeciﬁc ﬁndings, children may be
misdiagnosed with infectious encephalitis or autoimmune dis-
orders other than NMDAR encephalitis. In a study by Gable et al. of
10 cases of NMDAR encephalitis, four of whomwere children, MRI,
CSF, and EEG did not differentiate anti-NMDA-receptor encephali-
tis from viral etiologies, but some differenceswere noted in clinical
presentation.6 For instance, in differentiatingHerpes Simplex Virusvier Ltd. All rights reserved.
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with less psychiatric disturbances, and less likely to have
movement disorders and dysautonomia. In another recently
described case of NMDAR encephalitis occurring in a 15 year old
girl, the initial presentation was consistent with the NMDAR
encephalitis syndrome, but the patient subsequently experienced
10 relapses associated with extensive longitudinal myelitis and
optic neuritis, mimicking neuromyelitis optica.7
Here we describe presentation of NMDAR encephalitis in an 11
year-old female with explosive-onset epilepsy and unilateral
imaging ﬁndings mimicking Rasmussen syndrome (RS).
2. Case report
A previously healthy 11 year-old right handed white female
was transferred to our tertiary referral medical center for
evaluation and treatment of explosive onset of daily seizures
and psychiatric disturbances. Symptoms began with daily holo-
cranial headaches, neck pain, dysthymia, and hypersomnia for one
week. She then had a generalized tonic–clonic seizure at school.
She was brought to a local hospital, where initial evaluation
included head computed tomography (CT) that was normal and
lumbar puncture (LP) revealed a mild pleocytosis (18 wbc/dl) and
mildly elevated protein (67 g/dl). HSV-1 PCR was negative. She
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Fig. 1. Superior frontal-lobe brain MRI. Axial T2 FLAIR images (1.5 T, 5 mm slice thickness
presentation, (C) 20 days after presentation, (D) 88 days after presentation. At initial pr
lobes. Repeat scan 3 days later (B) demonstrates abnormal increased cortical signal and g
restriction or abnormal enhancement. At 20 days after presentation (C) the signal abno
(arrow, C). The more posterior superior frontal gyrus signal has resolved. At longer term
signal abnormality.remained hospitalized for the next three weeks due to daily
seizures. Seizures typically beganwith left leg tonic stiffening, then
spread to right leg and subsequently generalized. Multiple
anticonvulsant regimens during this period were largely ineffec-
tive in controlling seizure activity. The patient also developed
marked personality change, with profound abulia, periods of
catatonia, and bradykinesia. Serial brain MRI over a three week
interval revealed an enlarging area of focal FLAIR abnormality in
the right frontal lobe, which was not seen on the initial study
(Fig. 1). Bilateral medial frontal lobe involvement was also noted
(Fig. 2). This contralateral ﬁnding was not prominent on the
subsequent study, and was felt to be related to edema from her
seizures which were occurring daily at that time. Brain biopsy was
proposed in hopes for more accurate diagnosis, but parents elected
to transfer the patient to our center for a second opinion.
Transfer occurred three weeks after seizure onset (day 20).
Upon arrival, her physical exam was remarkable for profound
abulia, aprosody and paucity of speech. Choreoathetotic move-
ments of the left hand andmirrormovements of the left handwere
also noted. A second LP was performed and demonstrated a mild
elevation of opening pressure (22 cm water) but the pleocytosis
noted on the prior LP had resolved (2 wbc/dl). A serum and CSF
workup for autoimmune and paraneoplastic disorders was sent. A
24 h EEG revealed focal delta/theta slowing centrally (Fig. 3). On, TR: 10,002 ms, TE: 121 ms, TI: 2200 ms): (A) at initial presentation, (B) 3 days after
esentation (A) no deﬁnitive signal abnormality is identiﬁed in the superior frontal
yral swelling involving the superior frontal gyrus (arrows, B). There was no diffusion
rmality is more deﬁned anteriorly and extends into the subcortical white matter
follow up (D, 88 days after initial presentation), there is complete resolution of the
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Fig. 2.Medial frontal lobe brain MRI. Axial T2 FLAIR images (1.5 T, 5 mm slice thickness, TR: 10,002 ms, TE: 121 ms, TI: 2200 ms): (A) At initial presentation, (B) 3 days after
presentation, (C) 20 days after presentation, (D) 88 days after presentation. Subtle bilateral inferior medial frontal cortical signal abnormality was noted at presentation (A,
arrows). This progressed over three days with increasing signal and gyral swelling (B, arrows). No diffusion restriction or enhancement was noted. At 20 days after
presentation there is marked resolution of signal and gyral swelling withminimal increased signal remaining (C, arrows). At long term follow-up (88 days after presentation)
there is complete resolution of the signal changes (D).
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and an explosive onset of seizures, the diagnosis of RS was
considered. Positron emission tomography (PET) showed a focal
area of hypermetabolism in the right frontal lobe (Fig. 4)
correlating to the FLAIR signal abnormality noted on MRI
(Fig. 1). A computed tomography (CT) scan of the chest, abdomen,
and pelvis evaluating for occult malignancy did not identify any
tumor. However, the pelvic CT and subsequent thin-slice MRI of
same region did demonstrate a small paratubal cyst (Fig. 5). Serum
testing for NMDAR antibodieswas negative but strongly positive in
the CSF for NR1/NR2 subunits. Serum testing for other antibodies
associated with CNS paraneoplastic syndromes was negative,
including Hu, Ma1, Ma2, CV2, VGKC, and amphiphysin. Initial
neuropsychometric testing revealed signiﬁcant deﬁcits in proces-
sing speed and working memory.
Prior to identiﬁcation of anti-NMDAR antibodies in the CSF, the
patient was started on empiric high-dose intravenous methyl-
prednisolone. In the ensuing week, she experienced intermittent
episodes of hypoventilation and tachycardia. No further clinical
seizures were seen. After the third day of corticosteroid therewas a
plateau in her psychiatric symptoms and she occasionally spoke
voluntarily. After completion of ﬁve days of corticosteroid
treatment, an incomplete return to baseline prompted initiation
of ﬁve sessions of plasma exchanges performed on alternatingdays. At the end of these two courses of therapy, she continued to
be seizure free, choreoathetotic movements ceased, affect was
improved but still not back to baseline, and subtle left legweakness
was noted. She was discharged from the hospital in stable
condition after a total of eight weeks following initial presentation
at the outside hospital.
At three-month follow-up, the patient’s parents reported that
she continued to have improvement of personality and
cognition, although both still were not back to baseline. She
was now independent with activities of daily living. Neurop-
sychometric testing revealed ongoing deﬁcits in processing
speed and working memory, but these were signiﬁcantly
improved. She continued to have subtle left leg weakness.
Parents reported at this time a three-day history of hypersomnia
and fatigue concerning for possible relapse, prompting follow-
up MRI of the brain. The prior FLAIR abnormality in the right
frontal lobe was completely resolved (Fig. 1). Still, a ﬁve day
course of oral corticosteroids was prescribed, with resolution of
clinical symptoms. At six-month followup, routine imaging
surveillance with ultrasound demonstrated bilateral 1 cm
echogenic lesions in the ovaries. Exploratory laporotomy was
performed and the lesions were surgically removed under
ultrasound guidance which were conﬁrmed to be ovarian
teratomas by subsequent histological analysis.
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Fig. 3. Electroencephalography (EEG). Routine awake EEG using the 10/20 international system of electrode placement was performed 20 days after seizure onset. Shown is
AP bipolar montage, demonstrating central focal slowing.
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Fig. 4. Positron emission tomography (PET). PET images of the brain obtained after IV administrations of 7.53 mCi F-18 ﬂuorodeoxyglucose (FDG) 24 days after seizure onset.
(A) Color coded axial images, (B) PET–MRI fusion (with axial FLAIR sequence performed 20 days after initial presentation). Areas of asymmetric hypermetabolism are noted in
the superior right frontal lobe (A, arrows), corresponding to the areas of increased signal on recent MR imaging (B).
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Identiﬁcation of a recognizable clinical syndrome associated
with NMDAR antibodies in the CSF is an important discovery in
new onset pediatric epilepsy cases, particularly in girls. Our case
represents a mimic of the acute phase of Rasmussen syndrome
(RS). In a recent European Consensus Statement on RS, the acute
phase is described as a period of frequent seizures and neurological
deterioration.8 While seizures in RS classically present as epilepsia
partialis continua (EPC), this is not always the case. Twenty-four
percent of patients diagnosed with RS will have supplementary
motor area or premotor area-localizing seizures, as in our case.9
Current proposed diagnostic criteria of non-biopsy-proven RS
include focal seizures, unilateral cortical deﬁcits, unilateral EEG
ﬁndings, and hyperintense FLAIR signal on MRI.8 Our patient hadall of the features consistent with the diagnosis of RS except for
unihemispheric cortical atrophy. Reversible brain atrophy has
been reported in two women with anti-NMDA-receptor encepha-
litis.10 As in our patient, the ﬁnding of unilateral focal increased
metabolism of glucose on FDG-PET is suggestive of subclinical
seizures in RS but has also been described interictally in RS
patients.11 In one published report describing FDG-PET in NMDAR
encephalitis, bilateral areas of hypermetabolism were seen.12
Our patient exhibited many features described in acute RS.
Ignoring the psychiatric manifestations of anti-NMDA-receptor
encephalitis, or misinterpreting them as part of an epileptic
encephalopathy, could have led to a missed diagnosis. The typical
course of RS is relentless, and hemispherectomy is offered to
patients with a suspected diagnosis. Given the literature indicating
clinical improvement in most children with anti-NMDA-receptor
[()TD$FIG]
Fig. 5. Pelvis Imaging. (A) Coronal oblique T2 weighted MRI of the pelvis (slice
thickness: 3 mm, TR: 5200 ms, TE: 76 ms). (B) Coronal reconstruction, CT scan of the
pelvis. A small right sided paratubal cyst (arrows, A and B), but no deﬁnite solid
tumor, was identiﬁed.
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workup, treatment, and prognosis of the two disorders differ
signiﬁcantly.
Treatment of NMDAR encephalitis, beyond the decision to
remove the associated tumor identiﬁed in neoplastic cases,
consists of immunomodulatory therapy. Oral and intravenous
corticosteroids, intravenous immune globulin and plasmapheresis
have all been reported.4 Cyclophosphamide and rituximab have
been used in refractory cases.4,13 No prospective studies are
available to guide the clinician. Relapsing patients may show
improvement with repeated treatments.
In children, paraneoplastic disorders have generally been
considered extremely rare. NMDAR encephalitis in children is
more likely to be nonparaneoplastic than paraneoplastic. However,
as highlighted in this case, the neoplasm may be undetectable by
imaging at clinical presentation. Given the rapid contribution of
literature to this topic since it was described, the prevalence of
NMDAR encephalitis is likely to be underappreciated. This may be
especially true of patients with NMDAR antibodies who present
with less severe symptomology, since the diagnosis is usually
considered only in severe and puzzling cases. In a study of 19
young women with unexplained new onset epilepsy, ﬁve had
NMDAR antibodies.14 Four out of these ﬁve had psychiatric
disturbances consistentwith the syndrome. It would be interesting
to know if NMDAR encephalitis accounts for a similarly high
proportion of unexplained new-onset epilepsy in children. In 1992Sebire et al. published a case series of children with a syndrome of
intense dyskinesia, sleep disturbances, seizures, and regression,
who made an unexpected excellent recovery.15 Recently, Poloni
et al. described four children with the ‘‘Sebire syndrome’’, and
discovered two new cases of NMDAR encephalitis in this group.16
They postulate a link between NMDAR encephalitis and encepha-
litis lethargica as well. This data suggests that children with
otherwise unexplained new-onset epilepsy, especially with
explosive onset and associated with neuropsychiatric decline,
dyskinesias, or other encephalopathic symptoms, should be tested
for NMDAR antibodies so as to provide more accurate prognosis
and guide appropriate treatment. Our case demonstrates the
importance of continued imaging surveillance in presumed
nonneoplastic NMDAR encephalitis. Imaging surveillance should
be included in the plan of care regardless of response to
immunomodulatory therapy or absence of relapse; in our patient
associated bilateral ovarian teratomas became detectable during a
clinically-improved period without relapse.
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